Hormone sensitivity malignancy status (Z19) ICD-10-CM
The Z19 code range covers hormone sensitivity malignancy status with 3 ICD-10-CM diagnosis codes. 2 of them are billable and valid for claim submission in fiscal year 2026, and the category headers group them but cannot themselves be billed.
Code First
Certain conditions have both an underlying etiology and multiple body system manifestations due to the underlying etiology. For such conditions, the ICD-10-CM has a coding convention that requires the underlying condition be sequenced first followed by the manifestation. Wherever such a combination exists, there is a "use additional code" note at the etiology code, and a "code first" note at the manifestation code. These instructional notes indicate the proper sequencing order of the codes, etiology followed by manifestation.
- malignant neoplasm - see Table of Neoplasms, by site, malignant
Codes in the Z19 Range 3 codes · 2 billable
About the Z19 Code Range
ICD-10 code Z19 is used to indicate the status of a hormone-sensitive malignancy, capturing whether a cancer is influenced by hormone levels or hormone therapy. This code range is essential for documenting patients with cancers that respond differently depending on hormone sensitivity.
The codes Z19.1 and Z19.2 provide more specific details. Z19.1 is used when a patient has a hormone-sensitive malignancy, such as hormone-sensitive prostate cancer, where the tumor may respond to hormone treatments. In contrast, Z19.2 covers hormone-resistant malignancy status, indicating cancers like primary malignant hormone-refractory prostate neoplasms that do not respond to hormone therapies. These codes help healthcare providers and coders distinguish between hormone-responsive and hormone-resistant cancer statuses, supporting targeted treatment decisions and accurate medical records for conditions related to prostate malignancies and similar cancers influenced by hormones.
Questions About This Page
How many billable codes are in the Z19 range?
Of the 3 codes in this range, 2 are billable and valid for claim submission from October 1, 2025 through September 30, 2026. Category header codes group them but cannot be reported on claims.
What does the Z19 range classify?
The range classifies hormone sensitivity malignancy status. Each code links to its own reference page with billing status, MS-DRG grouping, coding notes, and clinical information.
Related References
Source: CMS FY 2026 ICD-10-CM Tabular List and order file, effective October 1, 2025 through September 30, 2026.
